Related Experiment Video
Updated: Jan 12, 2026
08:56
Development of New Therapeutic Applications Using Microfluidics
Published on: October 1, 2007
5.7K
Intermediaries and Development of Biopharmaceuticals: Evidence From the Innovation Policy in a Developing Country
Atiyeh Safardoust1, Fereidoun Mahboudi2, Soode Mirmohammadi3
1National Research Institute for Science Policy, Tehran, Iran.
The International Journal of Health Planning and Management
|November 5, 2025
Summary
Intermediaries are crucial for Iran's biopharmaceutical sector, addressing challenges in innovation policies related to human capital, funding, and networking. Strengthening these support systems can boost competitiveness and reduce import reliance.
Area of Science:
- Biopharmaceutical Innovation
- Innovation Policy
- Industry Development
Background:
- Iran's biopharmaceutical industry shows progress driven by innovation policies.
- Sustainable innovation is hindered by resource limitations, skill gaps, and funding access issues.
Purpose of the Study:
- Examine the role of intermediaries in supporting biopharmaceutical companies.
- Analyze how innovation policies impact technological capabilities, networking, human capital, and funding.
Main Methods:
- Qualitative approach with purposive sampling of 19 participants.
- Semi-structured interviews and thematic analysis (Braun & Clarke, 2006).
- Ensured data credibility via member checking, triangulation, and independent coding.
Main Results:
- Innovation policies advanced in production, networking, human capital, and funding, yet face challenges.
- Intermediaries (accelerators, tech centers, funds) address these challenges.
- Intermediaries provide training, financial support, facilitate collaboration, and build networks.
Conclusions:
- Strengthening intermediaries is key to enhancing innovation policy effectiveness.
- Targeted policies addressing real company needs can reduce import dependence.
- Improved innovation capacity can boost global competitiveness of Iran's biopharmaceutical industry.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
223
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
223
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
227
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
227
01:28Biopharmaceutics and Pharmacokinetics: Overview
3.3K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
3.3K
01:03Drug Control Governance: Regulatory Bodies and Their Impact
481
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
481
01:22Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
165
Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...
165
01:29Microorganisms in Medicine and Therapeutics
925
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
925